Clinical Trials Logo

Infection, Surgical Site clinical trials

View clinical trials related to Infection, Surgical Site.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05705843 Recruiting - Clinical trials for Infection, Surgical Site

IO vs IV Vancomycin in Tourniquetless TKA

Start date: January 25, 2023
Phase: Phase 4
Study type: Interventional

Purpose of this study is to compare the efficacy of intravenous and intraosseous antibiotic administration techniques during tourniquetless total knee arthroplasty.

NCT ID: NCT05499481 Recruiting - Clinical trials for Antibiotic Side Effect

Short Against Long Antibiotic Therapy for Infected Orthopedic Sites

SALATIO
Start date: September 15, 2022
Phase: Phase 3
Study type: Interventional

The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment: - SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy. - SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.

NCT ID: NCT04541394 Recruiting - Clinical trials for Infection, Surgical Site

Effectiveness and Clinical Application of MolecuLight Bacterial Fluorescence Imaging in Wound Debridement

Start date: February 17, 2021
Phase: N/A
Study type: Interventional

MolecuLight is a device that utilizes a special light which, when used on wounds, helps identify the regions which pathogenic bacterial counts are the highest. The device applies 405nm violet light which is harmless to the human tissue. When specific components in bacteria catches up the light, a photoluminescent reaction is triggered and the fluorescence light is caught by the camera on this device in real time. When treating an infected wound which requires debridement and/or reconstruction, traditionally surgeons rely on many clinical clues to judge the severity and region of infection. However, these clues, such as lab data, vital signs, bacterial culture growth, or infection symptoms/signs, are usually indirect and also require several days to be fully interpretated. The advantage of MolecuLight is its simple, direct, real-time, and flexible application, which is very important and valuable when treating an infected wound. We aim to add this device to our routines and see if the treatment course for these wounds can be more rapid and effective, and also utilize the countless potential of immediate bacterial identification in numerous aspects of our work.